Kevin A. Schulman, MD, MBA | Authors

Performing Economic Evaluations Alongside of Cancer Clinical Trials

July 01, 1998

Health care providers and financing organizations have become more aware of the resource constraints on the provision of medical services, thus increasing the importance of economic evaluations within the health care industry.[1,2] This has carried over to the evaluation of new, therapeutic strategies for cancer, which have traditionally been evaluated exclusively for safety and clinical efficacy.

Beyond Survival: Economic Analyses of Chemotherapy in Advanced, Inoperable NSCLC

February 01, 1998

Research shows that chemotherapy for inoperable non-small-cell lung cancer (NSCLC) improves survival. The economic implications of this treatment choice may be substantial. This paper reviews studies examining the cost-

Measuring the Cost-Effectiveness of Cancer Care

June 01, 1996

Historically, new therapeutic strategies for cancer have been evaluated on the basis of safety and clinical efficacy. However, the current national emphasis on efficiency of resource allocation has led to the inclusion of economic assessments in oncology studies. Economic assessments measure patients' health status and resource consumption associated with a therapeutic strategy, and combine these in a cost-effectiveness analysis. Study design can include prospective analysis of clinical trials, retrospective analysis of a clinical trial or administrative databases, or a decision analytic model. Economic analysis is being used increasingly in oncology and will continue to provide meaningful data to assist clinicians in determining the optimal treatment strategies for cancer patients and to help inform health policy decision-makers about the importance of specific cancer therapeutic strategies. [ONCOLOGY 9(6):523-538, 1995]

Economic Savings and Costs of Periodic Mammographic Screening in the Workplace

March 01, 1996

This paper is a very interesting economic analysis of workplace mammography screening programs. Especially important is the discussion of the effect of disease prevalence on the cost-effectiveness of workplace screening programs.